尤瑞克林联合巴曲酶治疗急性大脑中动脉脑梗死的近期临床疗效观察(1)
 |
| 第1页 |
参见附件(2965KB，3页)。
【摘要】 目的 探讨尤瑞克林联合巴曲酶治疗急性大脑中动脉脑梗死的近期疗效和安全性。方法 选择急性大脑中动脉脑梗死患者92例,随机分为联合治疗组(尤瑞克林+巴曲酶)32例、巴曲酶组31例、和对照组(常规治疗组)29例。观察3组治疗前后NIHSS评分(美国国立卫生院卒中量表)的变化。结果 3组治疗前NIHSS评分无差异，在治疗后14、28 d NIHSS评分显示：联合治疗组神经功能明显改善，巴曲酶组有所改善，对照组恢复最差，3组间比较有统计学差异。所有病例无严重不良反应发生。结论 尤瑞克林联合巴曲酶治疗急性大脑中动脉脑梗死安全、有效。
【关键词】 尤瑞克林; 巴曲酶；急性大脑中动脉脑梗死
Therapeutic effect of Urinary Kallidinogenase plus Bathoxobin on acute middle cerebral artery infarction
WEI Li-ping, XU Xiao-hui, LI Ya-juan,et al.
Department of Neurology, Central Hospital of Luoyang , Luoyang 471009,China
【Abstract】 Objective To observe the therapetic effect of Urinary Kallidinogenase plus Batroxobin in treatment of acute middle cerebral artery infarction Methods Ninty-two patients with acute middle cerebral artery infarction were randomly assigned into combined treatment group(32cases),batroxobin group(31cases)and control group(29cases).All patients had been treated with the conventional neurological treatment.The NIHSS were evaluated before treatment and at 14 days and 28 days after treatment.Results The NIHSS score was no significant btween 3 groups before treatment.14days and 28days after treatment the symptom improvement score in Urinary Kallidinogenase plus.Batroxobin group was the highest, Batroxobin group was better and control group was the lowest.That means the improvement of neurological deficit in Urinary Kallidinogenase plus Batroxobin was excellent.Conclusion The report suggest that Urinary Kallidinogenase plus Batroxobin show effectiveness on the patients with acute middle cerebral artery infarction
【Key words】 Urinary Kallidinogenase; Batroxobin; Acute middle cerebral artery infarction
大脑中动脉正常的管径只有2 mm,是大脑的主要供血动脉[1]，其闭塞后可引起严重的神经功能缺损，一旦错过溶栓时间窗其病死率、致残率均较高。目前的治疗方法疗效有限。我们用尤瑞克林联合巴曲酶治疗大脑中动脉脑梗死,取得较好疗效。现报告如下。
1 资料与方法
1.1 一般资料 选择2008年1月至2011年2月在我院神经内科住院的大脑中动脉脑梗死患者92例,随机分为联合治疗组(尤瑞克林+巴曲酶)32例、巴曲酶组31例、和对照组(常规治疗组)29例组。联合治疗组中：男22例、女例10,年龄39~79岁(65.24±10.28);伴高血压20例,糖尿病16例,冠心病7例,卒中史12例,M1段梗死17例，M2段梗死15例。巴曲酶组中：男23例，女8例,年龄40~80岁(63.43±8.29);伴高血压18例,糖尿病12例,冠心病5例,卒中史9例, M1段梗死15例，M2段梗死16例。对照组男20例、女9例,年龄41~81岁(7.75±8.35);伴高血压16例,糖尿病9例,冠心病8例,卒中史6例M1段梗死14例，M2段梗死15例。3组病例的年龄、性别、既往病史、伴发疾病积分及神经功能缺损评分均无统计学差异(P>0.05)。入选标准:①符合1995年全国脑血管病学术会议通过的诊断标准[2] ,②全部经过头颅CT或(和)MRI+MRA检查;证实为大脑中动脉脑梗死; ③排除脑出血, ④首次发病或既往发病的肢体瘫痪后遗症不影响神经功能评分的再次发病患者;⑤年龄18~82岁的住院患者,性别不限;⑥无全身严重并发症 ......
您现在查看是摘要介绍页，详见PDF附件(2965KB，3页)。